Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027736 | 0.92 | AURKA (0.49) | CCNE1CDK2CDK5AURKASMN1; SMN2 | |
| SCHEMBL5025190 | 0.87 | SMN1; SMN2 (0.42) | CCNE1CDK2CDK5NPSR1RXFP1 | |
| SCHEMBL5027769 | 0.85 | TSHR (0.45) | CCNE1CDK2CDK5AURKAHTT | |
| SCHEMBL5045081 | 0.84 | CCNE1 (0.42) | CCNE1CDK2CDK5SMN1; SMN2ALDH1A1 | |
| SCHEMBL5029591 | 0.83 | KCNJ5 (0.47) | CCNE1CDK2CDK5AURKAHTT | |
| SCHEMBL5046778 | 0.81 | CCNE1 (0.45) | CCNE1CDK2CDK5AURKAHTT | |
| SCHEMBL5025993 | 0.80 | SCD (0.45) | CCNE1CDK2CDK5SMN1; SMN2ALDH1A1 | |
| SCHEMBL27543447 | 0.76 | ALDH1A1 (0.51) | CCNE1CDK2CDK5NPSR1HTT | |
| SCHEMBL5041435 | 0.75 | AURKA (0.53) | CCNE1CDK2CDK5AURKAHTT | |
| SCHEMBL5027766 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRMEN1KMT2APSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | CCNE1 1042/4885CDK2 138/4885CDK5 393/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | CCNE1 199/4885CDK2 47/4885CDK5 187/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | CCNE1 106/4885CDK2 28/4885CDK5 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.